Your browser doesn't support javascript.
loading
Elevation of Neurodegenerative Serum Biomarkers among Hospitalized COVID-19 Patients
Jennifer A. Frontera; Allal Boutajangout; Arjun Masurkar; Rebecca A Betensky; Yulin Ge; Alok Vedvyas; Ludovic Debure; Andre Moreira; Ariane Lewis; Joshua Huang; Sujata Thawani; Laura Balcer; Steven Galetta; Thomas Wisniewski.
Affiliation
  • Jennifer A. Frontera; NYU Grossman School of Medicine
  • Allal Boutajangout; NYU Grossman School of Medicine
  • Arjun Masurkar; NYU Grossman School of Medicine
  • Rebecca A Betensky; New York University School of Global Public Health
  • Yulin Ge; NYU Grossman School of Medicine
  • Alok Vedvyas; NYU Grossman School of Medicine
  • Ludovic Debure; NYU Grossman School of Medicine
  • Andre Moreira; NYU Grossman School of Medicine
  • Ariane Lewis; NYU Grossman School of Medicine
  • Joshua Huang; NYU Langone Health
  • Sujata Thawani; NYU Grossman School of Medicine
  • Laura Balcer; NYU Grossman School of Medicine
  • Steven Galetta; NYU Grossman School of Medicine
  • Thomas Wisniewski; NYU Grossman School of Medicine
Preprint in English | medRxiv | ID: ppmedrxiv-21262985
ABSTRACT
INTRODUCTIONOlder adults hospitalized with COVID-19 are susceptible to neurological complications, particularly encephalopathy, which may reflect age-related neurodegenerative processes. METHODSSerum total tau, ptau-181, GFAP, NFL, UCHL1, and amyloid-beta(A{beta}-40,42) were measured in hospitalized COVID-19 patients without a history of dementia, and compared among patients with or without encephalopathy, in-hospital death versus survival, and discharge home versus other dispositions using multivariable Cox proportional hazards regression analyses. RESULTSAmong 251 patients, admission serum ptau-181 and UCHL1 were significantly elevated in patients with encephalopathy (both P<0.05) and total tau, GFAP, and NFL were significantly lower in those discharged home(all P<0.05). These markers correlated significantly with severity of COVID illness. NFL, GFAP and UCH-L1 were significantly higher in hospitalized COVID patients than in non-COVID controls with mild cognitive impairment or Alzheimers disease(AD). DISCUSSIONAge-related neurodegenerative biomarkers were elevated to levels observed in AD and associated with encephalopathy and worse outcomes among hospitalized COVID-19 patients.
License
cc_by_nc_nd
Full text: Available Collection: Preprints Database: medRxiv Type of study: Prognostic study Language: English Year: 2021 Document type: Preprint
Full text: Available Collection: Preprints Database: medRxiv Type of study: Prognostic study Language: English Year: 2021 Document type: Preprint
...